The 2021 Annual
PRIMO Meeting Agenda

The PRIMO meeting Co-Chairs and Steering Committee worked hard to curate an agenda to meet the educational needs of all attendees and focused on the following key areas:
  • Practical considerations of applying biomarkers and targeted therapy
  • Integration of immunotherapy, with a focus on novel management approaches
  • Patient selection, as well as timing and sequencing of therapy
  • Dealing with important trends, such as big data and defining value in cancer care
NOTE: All times listed are in Central Standard Time (CST)
3:00 PM – 3:05 PM
Meeting Welcome from Cancer Expert Now
Sanjiv Agarwala
3:05 PM – 3:10 PM
Program Overview
Hope S. Rugo & Julie Vose
3:10 PM – 3:20 PM
Women in Oncology Award Winner #1 Presentation
Hope S. Rugo & Julie Vose
Hematologic Malignancies - Julie Vose / Sagar Lonial
3:20 PM – 3:40 PM
Indolent and Aggressive NHL Including CAR-T
Julie Vose
3:40 PM – 4:00 PM
Smoldering MM and Early Therapy vs Observation
Sagar Lonial
4:00 PM – 4:20 PM
AML/MDS: Update on Therapy
Naval Daver
Product Theater
4:20 PM – 5:20 PM
Product Theater (Non-CME/CE)
Hematologic Malignancies (cont.)
5:20 PM – 5:40 PM
CLL: What is the Best Initial Therapy for a Newly Diagnosed patient?
Susan O’Brien
5:40 PM – 6:00 PM
Update on ALL Therapy
Brian Jonas
6:00 PM – 6:20 PM
Break I Visit the Virtual Exhibits
Gastrointestinal Malignancies – Rachna T. Shroff
6:20 PM – 6:40 PM
Colon Cancer - Divide and Conquer
Kanwal Raghav
6:40 PM – 7:00 PM
Hot Topics in Pancreatic and Biliary Cancer
Rachna Shroff
7:00 PM – 7:20 PM
Five Years In; How Far Reaching Have Biosimilars Been in the US?
Jorge J. Garcia
Product Theater
7:20 PM – 8:20 PM
Product Theater (Non-CME/CE)
Closing Remarks
8:20 PM – 8:25 PM
Close of meeting day 1
Hope S. Rugo & Julie Vose

3:00 PM – 3:05 PM
Meeting Welcome from Cancer Expert Now
Sanjiv Agarwala
3:05 PM – 3:10 PM
Program Overview
Hope S. Rugo & Julie Vose
3:10 PM – 3:20 PM
Women in Oncology Award Winner #2 Presentation
Hope S. Rugo & Julie Vose
Melanoma, Skin Cancers, RCC – Shane Morita / ?
3:20 PM – 3:40 PM
Melanoma: Keeping Up With the Data
Sanjiv Agarwala
3:40 PM – 4:00 PM
Sarcoma: Where are We Making Progress?
Shane Morita
4:00 PM – 4:20 PM
Medical Therapy for Head and Neck Cancers: Current Status
Edgardo Santos Castillero
Product Theater
4:20 PM – 5:20 PM
Product Theater (Non-CME/CE)
GU Cancers - Sanjiv Agarwala
5:20 PM – 5:40 PM
Bladder Cancer: Sequencing Therapeutic Choices
Ravi Madan
5:40 PM – 6:00 PM
RCC: A Surfeit of Riches – What’s a Clinician to Do?
Donald Trump
6:00 PM – 6:20 PM
Impact of COVID-19 on Cancer Care
Jessica MacIntyre
6:20 PM – 6:40 PM
Break I Visit the Virtual Exhibits
Lung - Paul A. Bunn
6:40 PM – 7:00 PM
Immunotherapy for Advanced NSCLC.
Luis Raez
7:00 PM – 7:20 PM
Matching Drugs to Targets in NSCLC
Jack West
7:20 PM – 7:40 PM
Therapeutic Advances in SCLC;
Paul Bunn
Product Theater
7:40 PM – 8:40 PM
Product Theater (Non-CME/CE)
Closing Remarks
8:40 PM – 8:45 PM
Close of meeting day 2
Hope S. Rugo & Julie Vose

3:00 PM – 3:05 PM
Meeting Welcome from Cancer Expert Now
Sanjiv Agarwala
3:05 PM – 3:10 PM
Program Overview
Hope S. Rugo & Julie Vose
3:10 PM – 3:20 PM
Women in Oncology Award Winner #3 Presentation
Hope S. Rugo & Julie Vose
Breast Cancer – Hope S. Rugo, MD
3:20 PM – 3:40 PM
New Directions in the Treatment of ER+ Breast Cancer
Sara Tolaney
3:40 PM – 4:00 PM
Updates in the Treatment of HER2+ Breast Cancer
DivSarah Hurvitz
4:00 PM – 4:20 PM
Triple Negative Breast Cancer: Immunotherapy and Novel Agents
Hope S. Rugo
Product Theater
4:20 PM – 5:20 PM
Product Theater (Non-CME/CE)
Breast Cancer (CONT.)
5:20 PM – 5:40 PM
Managing the Toxicity of Endocrine Therapy: Diet, Exercise, Sexual Health
5:40 PM – 6:00 PM
Genomics to Guide Therapy in Early and Late Stage Breast Cancer
Bill Gradishar
6:00 PM – 6:20 PM
Metastatic Survivorship Care
Adrienne M. Vazquez-Guerra
6:20 PM – 6:40 PM
Break I Visit the Virtual Exhibits
Other Women’s Cancers
6:00 PM – 6:20 PM
Metastatic Survivorship Care
Adrienne M. Vazquez-Guerra
7:00 PM – 7:20 PM
Other Gynecologic Malignancies
Closing Remarks
7:20 PM – 7:30 PM
Closing Remarks
Hope S. Rugo and Julie Vose

Registration

Registration Type Early
09/01/2020 - 10/31/2020
Regular
11/01/2020 - 12/31/2020
Late
01/01/2021 - 02/10/2021
Industry
$250
$450
$650

Join your colleagues and explore key developments in cancer care over the past 12 months as well as the anticipated advances that you and your patients will likely see in the upcoming year.

Target Audience

This activity has been designed to meet the educational needs of Academic and Community Practitioners, as well as Registered Nurses and Advanced Practice Registered Nurses, Pharmacists and Physician Assistants from all oncology specialties, treating all disease sites involved in the care of patients with cancer.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the rationale for mechanisms of action for molecular targeted and immunologic therapies used to treat cancer today;
  • Summarize recent advances in targeted and immunologic treatment of hematologic malignancies and solid tumors;
  • Identify patients who are appropriate candidates for targeted and immunologic therapies;
  • Implement strategies from a healthcare team approach to reduce treatment-related toxicities, and optimize patient outcomes;
  • Discuss promising targeted and immunologic approaches being tested in late-stage clinical trials.

PRIMO 2020
at a Glance

26 Conference Sponsors

THE PRACTICAL RECOMMENDATIONS IN IMMUNO AND MOLECULAR ONCOLOGY MEETING is a unique opportunity to receive CME/CE credits while staying ahead of the latest advances in immuno and molecular oncology.

The Annual PRIMO Meeting is designed to summarize key developments in cancer care over the past 12 months and features anticipated advances that you and your patients will likely see in the upcoming year.

Accredited by:

MEC Logo

Accreditation and Credit Statements

Jointly Accredited Provider Logo

In support of improving patient care, the Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE Credit Logo

This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credit for learning and change.

CME MOC Logo

This activity has been approved for AMA PRA Category 1 Credit(s)™

This Application-based activity has been approved for ACPE contact hours. This activity has been approved for ANCC contact hours.

AAPA Cat1 CME logo

The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for AAPA Category 1 CME credits.

DISCLOSURE POLICY

The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and ACCME Standards for Commercial Support, which requires everyone in a position of controlling the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests related to the activity content. MEC has implemented a mechanism to identify and resolve all conflicts of interest prior to the CME/CE activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity. CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.